A London clinic has become the first in Europe to roll out two Alzheimer’s wonder drugs privately after they were rejected ...

One described the approval of lecanemab as “no panacea” for patients, for example, while another went as far as to suggest that, in their eyes, donanemab offered “no net benefit” at all.

Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...

BTIG analyst Thomas Shrader has maintained their neutral stance on BIIB stock, giving a Hold rating on January 23.Invest with Confidence: ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

Japanese pharmaceutical company Eisai Co. and U.S. firm Biogen Inc. said Monday that a jointly developed Alzheimer's drug has ...

Antibiotics, antivirals, vaccinations and anti-inflammatory medication are associated with reduced risk of dementia, ...

The new study found anti-inflammatory drugs, such as ibuprofen, as well as antibiotics, antivirals and vaccinations, were associated with a lower risk of developing dementia ...

But two substances have been found to do the job. These are artificial antibodies called lecanemab and donanemab that bind specifically to beta-amyloid, flagging it for disposal. However ...

New drug approvals and a federal dementia care pilot program among the year's significant developments, according to the ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...